←
Guardant Health1,939 posts
Guardant Health avatar✓

Guardant Health ✓

@GuardantHealth

Conquering Cancer With Data

◷ Joined June 2012▧ 726 Photos and videos
Guardant Health avatar
Guardant Health@GuardantHealth·16h

Congratulations to our Chief Technology Officer Darya Chudova on being named one of Fierce’s 2026 Fiercest Women in Life Sciences! For more than a decade, Darya has helped shape Guardant’s technology with a focus on making a meaningful difference for patients. She brings that same care to her leadership, supporting the people behind the science & helping create opportunities for women leaders to grow & thrive.

Guardant Health avatar
Guardant Health@GuardantHealth·Nov 11

A deeper understanding of cancer biology can help answer treatment questions that genomic biomarkers alone may leave unanswered. Today we introduced new epigenomic applications for Guardant360® Liquid, powered by InfinityAI, to inform treatment decisions in advanced breast and lung cancers. Read more: bit.ly/4fsTePN

Post attachmentPost attachmentPost attachmentPost attachment
Milken Institute avatar
⟳ Guardant Health retweeted
Milken Institute@MilkenInstitute·Nov 10

In this #PowerOfIdeas #MIHealthSummit 2026 essay, AmirAli Talasaz, Co-founder and Co-CEO, Guardant Health, shows how easier screening tools like blood tests, backed by smart policy, can move the US from sick care to prevention. Stay tuned for posts from our other Power of Ideas authors as we near Future of Health Summit 2026. Find AmirAli's essay here: milkeninstitute.org/content-… Find the series here: milkeninstitute.org/events/f… #action #ideas #partnership #leadership #health

Post attachment
Guardant Health avatar
Guardant Health@GuardantHealth·Nov 10

New findings from the PRECISION study, published in @ESMO_Open, highlight how our Guardant360® Liquid & Guardant Reveal® tests can provide complementary insights for patients undergoing surgery for #ColorectalCancer metastases. Combining pretreatment genomic profiling and MRD testing identified 3 distinct risk groups, with estimated 2-year recurrence-free survival ranging from 78% to 9%. These findings deepen our understanding of recurrence risk & could help inform the development of more personalized treatment strategies. Details: bit.ly/4zxgSmi

0:55
Guardant Health avatar
Guardant Health@GuardantHealth·Nov 9

Turning complex data into clinically meaningful insights can open new possibilities in #CancerCare. Join us Thursday, November 12 for a #Webinar exploring how we’re using AI and machine learning to discover, validate & deploy novel multimodal biomarkers. We’ll share how this approach enables our epigenomic-based lung cancer subtyping feature & how oncologists are using insights from a single blood draw to detect subtype switching & inform more timely treatment decisions. Register: bit.ly/4BTb7B1

Post attachment
Guardant Health avatar
Guardant Health@GuardantHealth·Nov 5

Today, we announced our third quarter 2026 financial results, with 36% year-over-year revenue growth fueled by progress across our Oncology, Screening, & Biopharma & Data businesses. We also raised our full-year 2026 revenue guidance to $1.36–$1.37 billion, representing growth of 38–40%. Details: bit.ly/3V93XYP

0:41
Guardant Health avatar
Guardant Health@GuardantHealth·Nov 4

We’re pleased to welcome Kevin Sayer to our Board of Directors. As former CEO and current Executive Chairman of Dexcom, Kevin brings a strong record of advancing health technology and driving growth, & his expertise will be invaluable as we continue to pioneer innovations to shape the next era of #CancerCare. Details: bit.ly/4AdYaA9

Post attachment
Guardant Health avatar
Guardant Health@GuardantHealth·Nov 3

Our Shield™ blood test has received the 2026 #PrixGalien USA Award for Best Medical Technology! The award recognizes Shield’s impact in expanding patient choice and increasing #ColorectalCancer screening participation, celebrating the innovative science and dedication behind making CRC screening more accessible & closing the nation’s screening gap. Details: bit.ly/4z32JMP

0:30
Guardant Health avatar
Guardant Health@GuardantHealth·Oct 20

Strong collaborations drive new possibilities in #CancerCare. At #ESMO26, we, along with our research collaborators, will present 25 abstracts, including 5 rapid oral presentations, exploring advances in liquid biopsy across lung, colorectal, & gastric cancers. Reflecting the strength of our biopharma, academic, & public-private partnerships, these findings expand the evidence across MRD surveillance, treatment response, and resistance research, advancing our understanding of how genomic and epigenomic insights can inform cancer care. Details: bit.ly/486gejw

Post attachmentPost attachment
Guardant Health avatar
Guardant Health@GuardantHealth·Oct 15

#NewData reinforces the potential of Shield™ to close gaps in #ColorectalCancer screening, with 99% screening adherence in two rural clinics serving medically underserved communities and modeling results projecting more colorectal cancer deaths averted with blood-based screening than stool-based tests. Presented with our research collaborators at #ACG2026, this new modeling data builds on the growing evidence supporting Shield’s role in expanding screening participation and improving health outcomes. More: bit.ly/4s7DwyB

0:55
Guardant Health avatar
Guardant Health@GuardantHealth·Oct 8

Guardant360® CDx’s 31st companion diagnostic approval marks another #Milestone in its growing role in cancer care. Guardant360 CDx has received approval in Europe as a companion diagnostic to identify patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from @AstraZeneca's ETCAMAH™ (camizestrant). Following approvals in the U.S. and Japan, this milestone reinforces our commitment to enabling practice-changing ongoing monitoring across the world’s largest healthcare markets. More: bit.ly/4AXzGfx

0:30
Guardant Health avatar
Guardant Health@GuardantHealth·Oct 5

Understanding melanoma recurrence risk after surgery can help shape what comes next for patients. New results from the COSMOS-MEL01 study, published in @CRC_AACR, expand the evidence supporting Guardant Reveal® for molecular residual disease detection and recurrence monitoring in melanoma. The study demonstrated 81% sensitivity for distant recurrence and 100% post-treatment specificity, highlighting the potential of Reveal to inform more personalized surveillance strategies. More: bit.ly/3Vt96uM